Regulation of vascular reactivity by established and emerging GPCRs

被引:68
作者
Maguire, JJ [1 ]
Davenport, AP [1 ]
机构
[1] Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Ctr Clin Invest, Cambridge CB2 2QQ, England
关键词
D O I
10.1016/j.tips.2005.07.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The vascular system is rich in G-protein-coupled receptors (GPCRs), particularly Class 1 GPCRs, which are activated by an eclectic range of chemical entities including peptides. These chemical messengers can function in blood vessels as directly acting vasoconstrictors, directly acting vasodilators or indirectly acting vasodilators. During the past ten years >50 receptors previously designated as 'orphan receptors' have been paired with their cognate ligands. New transmitter systems are emerging with some displaying potent activity in the vascular system, including the vasoconstrictors apelin, motilin, neuromedin U, sphingosine-1-phosphate and urotensin-II, and the vasodilators ghrelin and nociceptin. All Class 2 GPCRs are activated by peptides. Those displaying Vasoactivity all function as directly acting vasodilators and include adrenomedullin and the emerging urocortin transmitters. Hypertension can persist despite treatment with combinations of blood-pressure-lowering drugs. Thus, it is likely that further as yet undiscovered transmitter systems will provide new targets for novel therapies or diagnosis.
引用
收藏
页码:448 / 454
页数:7
相关论文
共 70 条
[1]   Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites [J].
Alewijnse, AE ;
Peters, SLM ;
Michel, MC .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 143 (06) :666-684
[2]  
Alexander SPH, 2004, BRIT J PHARMACOL, V141, pS1
[3]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[4]   CRF and CRF receptors: Role in stress responsivity and other behaviors [J].
Bale, TL ;
Vale, WW .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2004, 44 :525-557
[5]   Urotensin II: Ancient hormone with new functions in vertebrate body fluid regulation [J].
Balment, RJ ;
Song, W ;
Ashton, N .
TRENDS IN COMPARATIVE ENDOCRINOLOGY AND NEUROBIOLOGY, 2005, 1040 :66-73
[6]   Fostering orphan receptors: an indispensable role for integrative, in vivo haemodynamic studies [J].
Bennett, T ;
Gardiner, SM .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (02) :140-145
[7]  
Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533
[8]   Provision of cardiovascular protection by ACE inhibitors: a review of recent trials [J].
Bertrand, ME .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (10) :1559-1569
[9]   Neuromedin U and its receptors: Structure, function, and physiological roles [J].
Brighton, PJ ;
Szekeres, PG ;
Willars, GB .
PHARMACOLOGICAL REVIEWS, 2004, 56 (02) :231-248
[10]   Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry [J].
Cayabyab, M ;
Hinuma, S ;
Farzan, M ;
Choe, H ;
Fukusumi, S ;
Kitada, C ;
Nishizawa, N ;
Hosoya, M ;
Nishimura, O ;
Messele, T ;
Pollakis, G ;
Goudsmit, J ;
Fujino, M ;
Sodroski, J .
JOURNAL OF VIROLOGY, 2000, 74 (24) :11972-11976